[Oral sucralfate administration for therapy and prevention of radiation-induced esophagitis: results of a placebo-controlled double-blind study].
Belka
C
C
D000284:Administration, Oral; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D004941:Esophagitis / Q000188:drug therapy*; D004947:Esophagus / Q000528:radiation effects*; D006801:Humans; D008479:Mediastinal Neoplasms / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000188:drug therapy*; D011837:Radiation-Protective Agents / Q000008:administration & dosage*; D013392:Sucralfate / Q000008:administration & dosage*; D017211:Treatment Failure
D000897:Anti-Ulcer Agents; D011837:Radiation-Protective Agents; D013392:Sucralfate
Orale Sukralfatgabe für die Therapie und Prophylaxe der strahleninduzierten Osophagitis: Ergebnisse einer placebokontrollierten doppelblinden Studie.